Remove Drug Development Remove Pharma R&D Remove Science
article thumbnail

EFPIA states AI rules must “enable not hinder” pharma R&D

Drug Discovery World

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has supported the use of artificial intelligence (AI) to deliver benefit for patients, life science companies and society, in response to the EU Artificial Intelligence (AI) Act.

article thumbnail

Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype

DrugBaron

After decades slowly developing in the shadows, featuring more often in science fiction novels than television news programs, the arrival of large language models, and ChatGPT in particular, thrust artificial intelligence into the national consciousness. Does AI improve decision making in drug R&D?

article thumbnail

Rethinking the pharma R&D lifecycle with AI in mind

Drug Discovery World

The inequality between near-zero-cost AI-driven drug discovery and skyrocketing costs for clinical trials and regulatory approval will create a bottleneck, stalling promising drugs from reaching patients unless AI is equally applied across the entire R&D lifecycle.